Lineage Cell Therapeutics (LCTX) Free Cash Flow (2010 - 2026)

Lineage Cell Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 63.21% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$22.6 million (up 1.0% YoY), while the FY2025 annual figure was -$19.4 million, up 17.82% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$8.1 million, down from -$5.4 million in the prior quarter.
• The five-year high for Free Cash Flow was $21.9 million in Q1 2022, with the low at -$11.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$5.8 million (2022), against an average of -$4.7 million.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 393.99% in 2022, then plunged 152.13% in 2023.
• Lineage Cell Therapeutics' Free Cash Flow stood at -$7.9 million in 2022, then increased by 22.68% to -$6.1 million in 2023, then declined by 12.93% to -$6.9 million in 2024, then rose by 22.1% to -$5.4 million in 2025, then plunged by 51.31% to -$8.1 million in 2026.
• Business Quant data shows LCTX's Free Cash Flow at -$8.1 million in Q1 2026, -$5.4 million in Q4 2025, and -$3.5 million in Q3 2025.